Dashboard
Manage Tickers

CING Cingulate Inc.

Nasdaq cingulate.com


$ 3.81 $ 0.18 (4.99 %)    

Friday, 31-Oct-2025 15:59:48 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 629.16 $ 3.02 (0.48 %)
DIA $ 475.58 $ 0.66 (0.14 %)
SPY $ 681.80 $ 2.23 (0.33 %)
TLT $ 90.21 $ -0.27 (-0.3 %)
GLD $ 368.20 $ -2.01 (-0.54 %)
$ 3.79
$ 3.61
$ 3.60 x 540
$ 4.10 x 5,800
$ 3.57 - $ 3.82
$ 3.02 - $ 6.01
173,470
na
20.51M
$ 2.46
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-19-2025 06-30-2025 10-Q
2 05-08-2025 03-31-2025 10-Q
3 03-27-2025 12-31-2024 10-K
4 11-07-2024 09-30-2024 10-Q
5 08-13-2024 06-30-2024 10-Q
6 05-08-2024 03-31-2024 10-Q
7 04-01-2024 12-31-2023 10-K
8 11-13-2023 09-30-2023 10-Q
9 08-14-2023 06-30-2023 10-Q
10 05-10-2023 03-31-2023 10-Q
11 03-10-2023 12-31-2022 10-K
12 11-14-2022 09-30-2022 10-Q
13 08-11-2022 06-30-2022 10-Q
14 05-12-2022 03-31-2022 10-Q
15 03-28-2022 12-31-2021 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

cingulate-releases-phase-3-trial-results-for-its-adhd-treatment-ctx-1301-showing-the-drug-met-its-primary-endpoints-showing-dose-dependent-improvements-on-adhd-symptom-and-severity-scales-and-demonstrated-effective-once-daily-symptom-relief-using-the-companys-precision-timed-release-technology
Cingulate Releases Phase 3 Trial Results F...
10/28/2025 12:04:13

Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company developing and advancing a pipeline of next-generation pharmaceutical...

cingulates-data-from-lead-adhd-candidate-ctx-1301-selected-for-podium-presentation-at-aacap-annual-meeting-in-chicago
Cingulate's Data From Lead ADHD Candidate ...
10/23/2025 20:48:34

Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company developing and advancing a pipeline of next-generation pharmaceutical...

roth-capital-maintains-buy-on-cingulate-raises-price-target-to-17
Roth Capital Maintains Buy on Cingulate, R...
10/15/2025 17:49:57

Roth Capital analyst Boobalan Pachaiyappan maintains Cingulate (NASDAQ:CING) with a Buy and raises the price target from $10...

Core News & Articles
12 Health Care Stocks Moving In Tuesday's ...
10/14/2025 21:06:16

cingulate-announces-that-us-fda-accepts-for-review-its-new-drug-application-for-ctx-1301-its-lead-adhd-treatment-candidate-for-children-and-adults
Cingulate Announces That U.S. FDA Accepts ...
10/14/2025 12:02:59

Cingulate Inc. (NASDAQ:CING) a biopharmaceutical company developing and advancing a pipeline of next-generation pharmaceutical ...

cingulate-enters-commercial-supply-agreement-with-bend-bio-sciences-for-manufacturing-of-ctx-1301-its-lead-drug-candidate-for-treating-adhd
Cingulate Enters Commercial Supply Agreeme...
09/17/2025 12:55:19

Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delive...

ascendiant-capital-maintains-buy-on-cingulate-raises-price-target-to-62
Ascendiant Capital Maintains Buy on Cingul...
08/22/2025 09:54:27

Ascendiant Capital analyst Edward Woo maintains Cingulate (NASDAQ:CING) with a Buy and raises the price target from $61 to $62.

cingulate-q2-eps-109-misses-084-estimate
Cingulate Q2 EPS $(1.09) Misses $(0.84) Es...
08/19/2025 13:46:13

Cingulate (NASDAQ:CING) reported quarterly losses of $(1.09) per share which missed the analyst consensus estimate of $(0.84) b...

cingulate-appoints-jennifer-callahan-as-interim-ceo-names-jay-roberts-executive-chairman
Cingulate Appoints Jennifer Callahan As In...
08/15/2025 13:15:05

Jennifer Callahan, Chief Financial Officer, appointed Interim CEOBoard member, Jay Roberts appointed Executive ChairmanKANSAS C...

cingulate-reports-termination-of-evp-and-coo-laurie-a-myers-effective-august-7-2025
Cingulate Reports Termination Of EVP And C...
08/08/2025 11:10:25

cingulate-submits-new-drug-application-to-fda--for-ctx-1301-for-treatment-of-adhd
Cingulate Submits New Drug Application To ...
08/06/2025 12:47:23

cingulate-receives-43m-waiver-from-fda-for-nda-for-ctx-1301
Cingulate Receives $4.3M Waiver From FDA F...
07/29/2025 12:01:29

cing-cingulate-enters-25m-purchase-agreement-with-lincoln-park
Cing Cingulate Enters $25M Purchase Agreem...
07/22/2025 21:18:37

-SEC Filing

Core News & Articles
12 Health Care Stocks Moving In Wednesday'...
06/18/2025 21:05:53

ascendiant-capital-maintains-buy-on-cingulate-raises-price-target-to-61
Ascendiant Capital Maintains Buy on Cingul...
05/27/2025 10:20:46

Ascendiant Capital analyst Edward Woo maintains Cingulate (NASDAQ:CING) with a Buy and raises the price target from $60 to $61.

cingulate-announces-efficacy-results-from-phase-3-pediatric-study-of-ctx-1301-in-adhd-showing-improvement-of-adhd-symptoms-at-week-5
Cingulate Announces Efficacy Results From ...
05/20/2025 12:05:30

roth-capital-maintains-buy-on-cingulate-lowers-price-target-to-11
Roth Capital Maintains Buy on Cingulate, L...
05/19/2025 18:07:02

Roth Capital analyst Boobalan Pachaiyappan maintains Cingulate (NASDAQ:CING) with a Buy and lowers the price target from $12...

cingulate-receives-formal-pre-nda-meeting-minutes-from-fda-for-ctx-1301-in-adhd
Cingulate Receives Formal Pre-NDA Meeting ...
05/14/2025 12:02:38

Details of the FDA's minutes include the following, all of which will be a matter of review during the approval process:The...

cingulate-q1-eps-104-misses-092-estimate
Cingulate Q1 EPS $(1.04) Misses $(0.92) Es...
05/08/2025 21:16:51

Cingulate (NASDAQ:CING) reported quarterly losses of $(1.04) per share which missed the analyst consensus estimate of $(0.92) b...

cingulate-announces-top-line-results-from-50mg-fedfast-study-of-ctx-1301-for-adhd-says-primary-endpoints-demonstrate-ctx-1301-can-be-taken-with-or-without-food
Cingulate Announces Top-Line Results From ...
04/29/2025 12:02:56

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION